US EditionPublished • loading... • Updated
Prelude Therapeutics to Present Breast Cancer Drug Data at AACR 2026
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Prelude Therapeutics to Present Breast Cancer Drug Data at AACR 2026
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) will present preclinical data on its experimental breast cancer drug candidate at the American Association for Cancer Research Annual Meeting 2026, the company announced. The poster presentation will feature data on PRT13722, an oral KAT6A selective degrader being developed for estrogen receptor-positive breast cancer. The AACR Annual Meeting is scheduled for April 17-22, with Pre…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
